GlassScriptPhysician profile
Padmaja Aradhya
NPI 1427022391
$14,774.41
in general payments reported to CMS, 2019-2025
64 companies · $2,854 in 2025
The $2,854 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,547 · 2020: $1,138 · 2021: $2,240 · 2022: $2,119 · 2023: $2,290 · 2024: $2,586 · 2025: $2,854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,612 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,612.36 |
| Education | $117.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,217.90 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Biogen, INC. | $1,026.76 | 2019-2025 | Vumerity, Plegridy, Spinraza |
| Abbvie INC. | $1,007.15 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Teva Pharmaceuticals USA, INC. | $998.01 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $778.94 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $697.52 | 2019-2025 | Ultomiris |
| Eisai INC. | $687.62 | 2019-2025 | |
| Lundbeck LLC | $602.21 | 2019-2025 | Vyepti, Rexulti |
| Supernus Pharmaceuticals, INC. | $507.65 | 2019-2024 | Qelbree, Qelbree |
| Pfizer INC. | $505.06 | 2023-2025 | |
| Sk Life Science, INC. | $485.94 | 2020-2025 | |
| Acadia Pharmaceuticals INC | $438.24 | 2019-2025 | Nuplazid, Daybue |
| Lilly USA, LLC | $399.53 | 2020-2025 | Kisunla, Amyvid, Emgality |
| Argenx US, INC. | $389.80 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Neurocrine Biosciences, INC. | $344.17 | 2019-2025 | Ingrezza, Ongentys |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Padmaja Aradhya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.